

## Q3'17 HIGHLIGHTS AND FINANCIALS

---

NOVEMBER 22<sup>ND</sup>, 2017


Nordic Nanovector ASA  
Kjelsåsveien 168 B, 0884 Oslo, Norway  
[www.nordicnanovector.com](http://www.nordicnanovector.com)  
IR contact: [tkvale@nordicnanovector.com](mailto:tkvale@nordicnanovector.com)

## Q3 2017 highlights

- ✓ Good progress towards planned start of the pivotal Phase 2b study PARADIGME in 2H 2017 to investigate Betalutin<sup>®</sup> in patients with 3<sup>rd</sup> line with R/R FL
- ✓ Recruitment of DLBCL patients into Phase 1 dose-escalation study with Betalutin<sup>®</sup> ongoing
- ✓ Preparations advancing for Phase 2 clinical trial to investigate the potential of Betalutin<sup>®</sup> combined with rituximab in 2<sup>nd</sup> line FL (ARCHER-1)
- ✓ Appointment of Dr. Reza Safaei as Head of Medical Affairs


# Operating loss reflecting progress in development activities

## Operating loss




- Higher clinical study activities for Betalutin®
- Increased activity level for commercialisation activities

## Operating expenses distribution YTD 2017



\*Development costs: preclinical, clinical, regulatory and CMC activities

# Solid cash position



\* USD/NOK 8.64

\*\* USD/NOK 7,95

## Upcoming events

**Carnegie Nordic Healthcare Day,  
New York**

5 December, 2017

**ASH poster presentation,  
Conference call**

9-12 December, 2017

**DNB Nordic Healthcare  
Conference, Oslo**

14 December, 2017

**Q4 and FY 2017 results**

27 February, 2018



*Nordic Nanovector's mission is to extend and improve the lives of patients with haematological cancers by developing and commercialising innovative Antibody Radionuclide Conjugates (ARC)*

---

Nordic Nanovector ASA  
Kjelsåsveien 168 B, 0884 Oslo, Norway  
[www.nordicnanovector.com](http://www.nordicnanovector.com)  
IR contact: [tkvale@nordicnanovector.com](mailto:tkvale@nordicnanovector.com)